Elizabeth C Finger, Julia MacKinley, Mervin Blair, Lindsay D Oliver, Sarah Jesso, Maria C Tartaglia, Michael Borrie, Jennie Wells, Isabel Dziobek, Stephen Pasternak, Derek G V Mitchell, Katherine Rankin, Andrew Kertesz, Adam Boxer
OBJECTIVE: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal dementia (FTD). METHODS: We conducted a randomized, parallel-group, double-blind, placebo-controlled study using a dose-escalation design to test 3 clinically feasible doses of intranasal oxytocin (24, 48, or 72 IU) administered twice daily for 1 week to 23 patients with behavioral variant FTD or semantic dementia (clinicaltrials...
January 13, 2015: Neurology